The results are described of prolonged corticosteroid treatment in 52 patients with pulmonary sarcoidosis observed for a mean duration of 10-5 years from diagnosis. Twenty of the patients -were treated for less than one year, the remainder for a mean of five years. The mean length of observation after discontinuing treatment was 5*5 years. Selection of patients for treatment was based on (1) evidence from radiographic observation, even for two years or more, that the disease was progressive so that spontaneous remission was improbable; and (2) evidence of disturbed lung function, especially the onset of dyspnoea or an impaired diffusing capacity. Treatment, conveniently with prednisone at a maintenance dose of about 15 mg. daily, should be continued for at least a year and often for much longer until withdrawal is not followed by radiographic relapse. Such treatmnent does not increase the chance of a complete remission even when given at an early stage of the disease; and relief of dyspnoea is unpredictable and seldom considerable. But prolonged treatment will halt progressive lung destruction and appears to curb the eventual mortality.
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Corticosteroids are well known to suppress the follicles of sarcoidosis and to improve the chest radiograph when the lungs are actively affected. Whether they can arrest progressive pulmonary sarcoidosis or alter its course in the long run, let alone reduce its mortality, has yet to be shown. While a controlled trial might supply the answer, we doubt whether the results could be reliable. Even with a large series of patients available, relatively few need treatment and, among those who do, the disease evolves so slowly in this country that many years would pass before statistics could be collected. What we have done instead is to compare, over a few years, the outcome in a small group of treated patients with that in a similar untreated group seen shortly before corticosteroids became available and who had already been reported (Smellie and Hoyle, 1960 Hoyle, 1960) . Twenty of the former group were first reported in 1955 (Hoyle, Dawson, and Mather, 1955) after receiving short courses of cortisone when ikequests for reprints should be sent to H. S., Royal Infirmary, Doncaster it was introduced. Some of these have been treated again for longer periods and are included for comparison of their eventual outcome with that of untreated patients. Twenty of the 52 patients were treated for less than a year, the remaining 32 for longer, with a mean of 5 years (range I to 13-7 years). We did not attempt to standardize the time, preferring to decide for each patient on the merits of his case. The mean length of observation from the time of discontinuing steroid treatment in those patients in whom this was possible was 5-5 years (range 1-7 to 11 years).
Initial investigation was made in the usual way and histological evidence of sarcoidosis was found in 46 patients. Dyspnoea was measured before and after treatment by grades already described (Smellie, Apthorp, and Marshall, 1961) . The 52 treated patients were observed for a mean duration of 10-5 years (range 2 to 25 years). They were treated solely for their lung disease, except 13 with ocular sarcoidosis and three with hypercalcaemia whose lungs or hilar lymph nodes were also affected.
Treatment was usually started in hospital with a daily dose of 150 mg. cortisone (26 patients) or 30 mg. prednisone (26 patients). Chest radiographs were taken monthly at first. When maximum improvement was found-in about three months as a rule-the corticosteroid was reduced gradually by monthly steps of 10 to 20 mg. cortisone or 2 5 to 5 mg. prednisone to a maintenance level of about 50 to 75 mg. cortisone or 10 to 15 mg. prednisone daily. Occasionally as little as 5 mg. prednisone was found to be enough. 519
The effects of treatment, and of relapse when treatment was stopped, were judged mainly by radiographic changes, dyspnoea, and lung function. The mortalities of the treated and untreated groups were also compared.
RESULTS
RADIOGRAPHIC COURSE A straight comparison between the radiographic course of 52 treated patients and 77 untreated ones (from Smellie and Hoyle, 1960) in Table I shows that fewer treated patients achieved radiographic clearing. Failure to improve, or even deterioration, was commoner in the treated group. This was a false impression, however, for the treated group included some who had advanced disease when given short courses of treatment; and also some who were treated initially within two years of discovery of their disease, a period within which spontaneous remission is now well known to occur (Smellie and Hoyle, 1960) . If the outcome for patients treated within two years of discovery is compared with that of the untreated group (Table  II) then it can be inferred that treatment did not increase the chance of full remission. lasting benefit as opposed to mere radiographic improvement. Further deaths may occur, but this group has already been under surveillance for a mean time of 14-5 years, as opposed to the mean of 4 years for the untreated series.
EFFECT OF CORTiCOSTEROIDS ON DYSPNOEA Dyspnoea on exertion is the chief symptom of progressive pulmonary sarcoidosis. Thirty-three of our 52 patients complained of this. Only eight had any symptomatic relief during treatment and only four claimed complete relief, a disappointing result even allowing that 23 of the 33 already had some radiographic evidence of pulmonary fibrosis. Among the few who gained relief this was unrelated to radiographic improvement. Indeed, five of the eight patients who were improved had less than 50% clearing of their shadows and one was unchanged.
The results of lung function studies in some of these patients have already been reported (Marshall, Smellie, Baylis, Hoyle, and Bates, 1958; Smellie et al., 1961; Hamer, 1963) . RELAPSE ON WITHDRAWAL OF TREATMENT When treatment was stopped or reduced excessively, 34 of 47 patients showed radiographic evidence of subsequent relapse. Nine of these had failed to show any improvement, so that the appearances were worse when they relapsed after treatment than they were before. In an attempt to explain why some patients did not relapse after withdrawal of corticosteroids we have analysed the presence or absence of relapse in relation to (1) the presence of pulmonary fibrosis before treatment began; (2) the maximum therapeutic effect on the pulmonary lesions; (3) the known duration of the disorder before treatment; (4) the duration of treatment; and (5) the extent of the disease judged by the presence of extrapulmonary lesions. (Smellie et al., 1961) . Grievous dyspnoea has been proposed as an indication for using corticosteroids (American Thoracic Society, 1960; Scadding, 1961 ), but we are convinced that this is worth while only in so-called alveolar capillary block due to acute sarcoidosis as seen chiefly in North America. Patients with severe pulmonary fibrosis in our hands have not improved. There is a chance of relief with lesser grades attributable to infiltration or to less severe fibrosis, although these imply some permanent lung damage. But then the aim is rather the prevention of further fibrosis and its complications and not just the relief of dyspnoea, which a minority only will experience.
It is agreed generally that corticosteroids have no more than a suppressive action on the epithelioid cell follicle of sarcoidosis. The main evidence is that complete radiographic clearing of shadows due to these lesions does not occur more often in patients treated with corticosteroids than would be expected from what we know of the natural course of the disorder (Tables I and II) . Scadding (1961) , James (1961) , and Sones and Israel (1961) have made similar observations. There is other evidence also; for we found relapse to be the rule among patients whose chest radiographs showed improvement short of complete clearing after withdrawal of corticosteroids (Table IV) , while those achieving complete clearing did not relapse, presumably because their disease remitted spontaneously. This assumption is supported by the significantly greater risk of relapse among patients treated after preliminary observation for two years, who are therefore unlikely to undergo spontaneous remission. That patients treated for more than a year had a greater risk of relapse is probably another expression of this principle: 21 of the 22 in this category who relapsed were observed for more than two years before treatment, but only two of the five who did not relapse.
About half our patients (28 of 52) improved radiographically to. a varying degree (Table I) . Stricter comparison with an untreated series showed that, of those who were treated, about half improved radiographically, but none of those who were untreated (Table IV) . Moreover, only one of the treated patients has died of respiratory failure, compared with five of the untreated. While this untreated group may not be regarded as a control series in the strict sense, it merits comparison for two reasons: (a) both groups were first followed for three years in which they were found to have persisting pulmonary lesions, thus virtually excluding the possibility of spontaneous remission; and (b) the untreated group comprised patients seen before corticosteroids were generally available and whose outcome was published (Smellie and Hoyle, 1960) before work began on the analysis of the present series, thus obviating bias on our part. Weighing the eventual outcome for this group of untreated patients against the risks and apparent benefits of treatment, we think the advantage lies with treatment.
The prime difficulty is to single out those patients who need treatment from those who do not. Better understanding of the outlook (Sones and Israel, 1961 ; Scadding, 1961 ; James, 1961; Lofgren and Stavenow, 1961; Smellie and Hoyle, 1957) has gone some way to help. It follows one of three main courses (Hoyle, 1961) A patient whose record illustrates the problems involved was a man (Mr. W. D.) of 28 found to have enlarged hilar nodes and bilateral pulmonary infiltration by mass radiography in January 1955. He also had enlarged lymph nodes in the neck, from one of which a biopsy confirmed the diagnosis of sarcoidosis: and a bone lesion was found radiographically in a terminal phalanx. He was mildly dyspnoeic on exertion when first seen. By March 1956 the pulmonary infiltration had increased and there was also some radiographic evidence of fibrosis (Fig. 1) . Bronchoscopy revealed a partially stenosed right upper lobe bronchus. Treatment with prednisone led rapidly to radiographic improvement and lessening of dyspnoea (Fig. 2) . A year later, in March 1957, his treatment was gradually stopped, to be followed by deterioration within a month (Fig. 3) . Treatment was restarted just as an anterior segmental collapse in the right upper lobe complicated the picture. Despite treatment this segment has remained collapsed, though, apart from this, radiographic improvement (Fig. 4) 
